Market Overview

Deciphera Pharma Scores A Sell-Side Recommendation

Deciphera Pharma Scores A Sell-Side Recommendation
Benzinga's Top Upgrades, Downgrades For August 7, 2018
50 Biggest Movers From Friday
Loxo Oncology: Out Of The Frying Pan And Into The Fire, Part 1 (Seeking Alpha)

Deciphera Pharmaceuticals Inc (NASDAQ: DCPH)’s kinase switch control platform has largely gone unnoticed on the Street.

The nascent portfolio caught an analyst's attention this week. 

The Rating

B Riley analyst Madhu Kumar initiated coverage on Deciphera with a Buy rating and $43 price target.

The Thesis

The analyst expects Deciphera’s DCC-2618 to post positive Phase 3 results in fourth-line gastrointestinal stromal tumors in 2019 and to start Phase 3 studies for second-line GIST in the latter half of 2018.

Phase 1 studies for the fourth-line indication demonstrated efficacy in disease control rate and early progression-free survival data. Early results in the second-line indication lend additional confidence in success against Pfizer Inc. (NYSE: PFE)’s Sutent.

“Consequently, the second-line opportunity for DCC-2618 could provide a critical edge in the GIST market, particularly in relation to competing c-Kit/PDGFRα TKI avapritinib from Blueprint Medicines Corp (NASDAQ: BPMC), for which Phase 3 studies in third-line GIST, versus Stivarga from Bayer, are guided to start in the first half of 2018,” Kumar said in a Thursday note.

“Taken as a whole, we see a broader opportunity for DCC-2618 in GIST in the second-line setting.”

Price Action

At the time of publication, Deciphera shares were up 0.8 percent at $28.93.

Related Links:

Argus Downgrades Biogen On Trial Delays, Competition In MS, Alzheimer's Drugs

Morgan Stanley Targets New All-Time High For Bristol-Myers, Upgrades To Overweight

Latest Ratings for DCPH

Aug 2018Canaccord GenuityInitiates Coverage OnBuy
Jun 2018B. Riley FBRDowngradesBuyNeutral
Jun 2018JP MorganMaintainsOverweightOverweight

View More Analyst Ratings for DCPH
View the Latest Analyst Ratings

Posted-In: B Riley Madhu KumarAnalyst Color Biotech Price Target Initiation Analyst Ratings General Best of Benzinga


Related Articles (BPMC + DCPH)

View Comments and Join the Discussion!

A Keystone Moment for the Market, Or Is This 'Small Potatoes?'

BofA: Concerns For Kimco Realty In 2018, 2019 Justify Downgrade